Suven Pharmaceuticals Ltd
NSE:SUVENPHAR

Watchlist Manager
Suven Pharmaceuticals Ltd Logo
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Watchlist
Price: 1 259.15 INR -2.18% Market Closed
Market Cap: 320.5B INR
Have any thoughts about
Suven Pharmaceuticals Ltd?
Write Note

Suven Pharmaceuticals Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Suven Pharmaceuticals Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Total Equity
â‚ą20.5B
CAGR 3-Years
20%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Equity
â‚ą282.5B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Equity
â‚ą283.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Equity
â‚ą691.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Equity
â‚ą75B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
12%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Equity
â‚ą93.6B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Suven Pharmaceuticals Ltd
Glance View

Market Cap
320.5B INR
Industry
Pharmaceuticals

Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana and currently employs 1,193 full-time employees. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.

SUVENPHAR Intrinsic Value
402.41 INR
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Suven Pharmaceuticals Ltd's Total Equity?
Total Equity
20.5B INR

Based on the financial report for Mar 31, 2024, Suven Pharmaceuticals Ltd's Total Equity amounts to 20.5B INR.

What is Suven Pharmaceuticals Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
28%

Over the last year, the Total Equity growth was 18%. The average annual Total Equity growth rates for Suven Pharmaceuticals Ltd have been 20% over the past three years , 28% over the past five years .

Back to Top